267 related articles for article (PubMed ID: 20828379)
41. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
[TBL] [Abstract][Full Text] [Related]
42. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.
Wang S; Pashtan I; Tsutsumi S; Xu W; Neckers L
Cell Cycle; 2009 Jul; 8(13):2050-6. PubMed ID: 19502802
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
44. Novel mechanism of attenuation of LPS-induced NF-κB activation by the heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells.
Thangjam GS; Dimitropoulou C; Joshi AD; Barabutis N; Shaw MC; Kovalenkov Y; Wallace CM; Fulton DJ; Patel V; Catravas JD
Am J Respir Cell Mol Biol; 2014 May; 50(5):942-52. PubMed ID: 24303801
[TBL] [Abstract][Full Text] [Related]
45. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
Cervantes-Gomez F; Nimmanapalli R; Gandhi V
J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
[TBL] [Abstract][Full Text] [Related]
46. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
47. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
Faingold D; Marshall JC; Antecka E; Di Cesare S; Odashiro AN; Bakalian S; Fernandes BF; Burnier MN
Clin Cancer Res; 2008 Feb; 14(3):847-55. PubMed ID: 18245548
[TBL] [Abstract][Full Text] [Related]
48. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
49. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
50. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
51. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
52. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
53. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
54. HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.
Mohammadi A; Yaghoobi MM; GholamhoseynianNajar A; Kalantari-Khandani B; Sharifi H; Saravani M
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):62-67. PubMed ID: 27894402
[TBL] [Abstract][Full Text] [Related]
55. Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model.
Lee WJ; Lee JH; Ahn HM; Song SY; Kim YO; Lew DH; Yun CO
Plast Reconstr Surg; 2015 Sep; 136(3):328e-337e. PubMed ID: 26313837
[TBL] [Abstract][Full Text] [Related]
56. RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.
Alfano L; Guida T; Provitera L; Vecchio G; Billaud M; Santoro M; Carlomagno F
J Clin Endocrinol Metab; 2010 Jul; 95(7):3552-7. PubMed ID: 20444924
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
[TBL] [Abstract][Full Text] [Related]
58. HSP90 as a novel therapeutic target for posterior capsule opacification.
Li J; Xue W; Wang X; Huang W; Wang XX; Li H; Cui X; Li M; Mu H; Ren Y; Zhang F; Hu Y
Exp Eye Res; 2019 Dec; 189():107821. PubMed ID: 31589841
[TBL] [Abstract][Full Text] [Related]
59. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
60. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
